ClinicalTrials.gg
TerminatedNCT01905592BRAVOUpdated Nov 15, 2022Results posted

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

A Phase 3 interventional study of niraparib and Physician's choice in Neoplasms, Breast, Carcinoma of Breast and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, sponsored by Tesaro, Inc.. Terminated at 104 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-15.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated due to futility.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing niraparib in Breast Neoplasms — 6 open to participants now, 11 under way, 1 of them phase 3. niraparib · Breast Neoplasms.

Enrollment
3rd of 20
216 · median 27
Started
2014
the only one that year
Phase 3
2 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
3 of 20
Tesaro, Inc.

Among the 20 studies testing niraparib in Breast Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2014, is one of 2 in phase 3, and was the 2nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 20 studies testing niraparib in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing niraparib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice

Read the detailed description

This is a phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. Niraparib is an orally active PARP inhibitor. Niraparib (in a 2:1 ratio) will be administered once daily continuously during a 21-day cycle. Physician's choice will be administered on a 21-day cycle. Health-related quality of life will be measured. The safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values.

03

Conditions studied

  • Neoplasms, Breast
  • Carcinoma of Breast
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • Ovarian Neoplasms

Keywords

  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • PARP Inhibitor
  • BRCA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Germline BRCA1 or BRCA2 mutation; patients with unknown BRCA status who meet NCCN BRCA screening criteria will be screened for BRCA mutation.
  2. or cytologically confirmed -negative or locally advanced disease that is not amenable to resection or radiation with curative intent.
  3. Up to 2 prior cytotoxic regimens for advanced or metastatic breast cancer; patients with no prior cytotoxic regimens for advanced or metastatic disease will only be allowed if they during or within 12 months of (neo-) cytotoxic therapy.
  4. Prior therapy should have included a taxane and/or anthracycline (unless to those) in the neoadjuvant, adjuvant, or advanced/metastatic setting.

    a. Hormone receptor positive patients must also have hormone resistant disease; either relapsed while on adjuvant endocrine treatment, or within one year of completing adjuvant endocrine treatment, or progression on at least one line of endocrine treatment for advanced cancer.

  5. performance status 0-2
  6. Adequate bone marrow, kidney and liver function

Exclusion criteria

Exclusion Criteria:

  1. Patients with platinum resistant cancer
  2. Symptomatic uncontrolled
  3. Prior diagnosis of Stage IV ovarian cancer; Stage III ovarian cancer must have a 5-year disease-free interval; Stage II ovarian cancer must have a 2-year disease-free interval
  4. Known to the components of niraparib
  5. Invasive cancer other than breast cancer within 2 years (except basal or squamous cell carcinoma of the skin that has been definitely treated)
  6. Pregnant or breast feeding patients
  7. patients
  8. Known active or C
  9. Prior treatment with a PARP inhibitor
  10. Known history of myelodysplastic syndrome (MDS).
  11. known and persistent (>4 weeks) >/= grade 3 toxicity or fatigue from prior cancer treatment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Active comparator
    Physician's choice

    Physician may select from 4 active comparators

    Drug: Physician's choice

  • Experimental
    niraparib

    Patients will be randomized 2:1 to receive niraparib 300 mg (3x100 mg capsules) once daily for 21 continuous days

    Drug: niraparib

Interventions

  • 300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops

    Also known as: formerly MK-4827

  • DrugPhysician's choice

    Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) - Central Review Assessment

    The primary objective of this study is to compare progression-free survival (PFS), as assessed by blinded central review, of participants with advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gBRCA mutation breast cancer when treated with niraparib as compared to those treated with physician's choice single agent chemotherapy standards (eribulin, vinorelbine, gemcitabine or capecitabine). PFS is defined as the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier as per Response evaluation criteria in solid tumors (RECIST) version (v)1.1 as determined by central review assessment. Progressive Disease is defined as at least a 20 percent (%) increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including Baseline) and an absolute increase of \>= 5 millimeter (mm).

    Time frame: From the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier, up to 4 years

Secondary outcomes

  1. Overall Survival

    Overall Survival (OS) was defined as the time from randomization to the date of death of any causes.

    Time frame: From treatment randomization to date of death of any cause, up to 4 years

  2. Number of Participants With Central BRCA Mutation Status

    Blood samples were collected to evaluate central BRCA mutation status of participants. Baseline was defined as the most recent non-missing measurement prior to or on the first administration of study drug. Number of participants with central BRCA mutation status as BRCA1 positive only, BRCA2 positive only, Rearrangement only, BRCA1 and BRCA2 positive, BRCA1 positive and rearrangement, and BRCA2 positive and rearrangement were reported.

    Time frame: At Baseline (Cycle 1 Day1) (Cycle duration was 21 days)

  3. Number of Participants With Serious Adverse Events (SAE) and Non-serious Adverse Events (Non-SAE)

    An adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect in a participant, whether or not considered related to the protocol treatment, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing participant hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an medically important event or reaction as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.

    Time frame: Up to 7 years

  4. Progression Free Survival (PFS) - Investigator Assessment

    PFS is defined as the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier as per RECIST version 1.1 as determined by Investigator assessment. Progressive Disease is defined as at least a 20 % increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including Baseline) and an absolute increase of \>= 5 mm.

    Time frame: Assessed up to 4 years

  5. Time to Treatment Failure

    Time to treatment failure was defined from the date of randomization to progression or discontinuation of treatment for any reason, including but not restricted to disease progression, treatment toxicity and death.

    Time frame: Date of randomization to discontinuation of treatment for any reason, up to 4 years

  6. Overall Response Rate (ORR)

    ORR was defined as the percentage of the participants who achieved a complete response (CR) or partial response (PR) to treatment evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR)=disappearance of all target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. Partial Response (PR)= at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the Baseline sum of diameters. Percentage values are rounded off up to 1 decimal.

    Time frame: Up to 4 years

  7. Duration of Response (DOR)

    Duration of response was defined as the time from first documentation of response (confirmed CR or PR) until the time of first documentation of disease progression by RECIST v1.1 or death by any cause.

    Time frame: Up to 4 years

  8. Number of Participants With Serious Adverse Events Related to New Malignancy

    The number of participants with serious adverse events related to new malignancy were reported.

    Time frame: Up to 7 years

  9. Number of Participants With Subsequent Anticancer Therapies

    The number of participants with subsequent anticancer therapies were evaluated. Data has been reported as per following categories: any new anitumoral therapy, any chemotherapy, any radiotherapy, any surgery, any hormonal therapy, any targeted agents, and any other treatment. Participants may have received more than one subsequent therapies.

    Time frame: Up to 7 years

Other outcomes

  1. Number of Participants With Minimally Clinically Important Difference (MCID) Status in European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-C30 (EORTC-QLQ-C30)

    The number of participants with MCID status in EORTC-QLQ-C30 was planned to be evaluated.The EORTC- QLQ-C30 includes 30-items with single and multi-item scales. These include five functional scales (physical functioning, role functioning cognitive functioning, emotional functioning and social functioning), three symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss and financial difficulties). Response options are 1 to 4. The average score can be transformed to 0 to 100, a high score for functional scales/ GHS/QoL represents better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represents significant symptomatology.

    Time frame: Up to 7 years

  2. Number of Participants With Euroqol 5 Dimension 5 Level (EQ-5D-5L) Dimension Scores by Visit

    The number of participants with EQ-5D-5L scores by visit were planned to be evaluated. EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility,self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale(no problems, slight problems, moderate problems, severe problems and extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were to be converted to a single index score. Range for EQ-5D-5L index score is 0 (worst health) to 100 (best health), higher the score better the health status.

    Time frame: Up to 7 years

  3. Number of Participants With Any Subsequent Therapies Post Discontinuation of Study Treatment and Association With Potential Survival Related Outcomes

    The number of participants with any subsequent therapies post-discontinuation of study treatment and association with potential survival related outcomes were planned to be evaluated.

    Time frame: Up to 7 years

  4. Number of Participants With Presence of Genetic and Non-genetic Biomarkers

    Biomarkers include germline and tumor mutations including somatic BRCA1 and 2 mutations, reversion mutations, loss of heterozygosity as well as genome landscape and transcriptional or functional measures of homologous recombination (HR) deficiency were planned to be evaluated.

    Time frame: Up to 7 years

  5. Number of Participants With Germline BRCA1 and BRCA2 Mutation Status in Association With Survival Related Outcomes

    Participants with germline BRCA1 and BRCA2 mutation status in association with survival related outcomes were planned to be evaluated.

    Time frame: Up to 7 years

07

Results

Posted Aug 27, 2020
Limitations and caveats
IDMC interim analysis concluded that concerns with the quantity and quality of data in the control arm precluded meaningful comparative analyses and generation of a clinically useful endpoint, therefore enrollment was ended prematurely.

Participant flow

Previously treated, human epidermal growth factor receptor 2 HER2 negative, germline Breast Cancer gene (gBRCA) mutation positive breast cancer participants were enrolled. The study was terminated due to futility.

Participant flow — Overall Study
MilestonePhysician's ChoiceNiraparib
Started71135
Completed00
Not completed71135
Withdrew: Disease progression51110
Withdrew: Toxicity116
Withdrew: Physician decision02
Withdrew: Start of new anti-cancer treatment10
Withdrew: Protocol violation01
Withdrew: Sponsor's decision11
Withdrew: Not treated73
Withdrew: Withdrawal by subject102

Outcome measures

PrimaryProgression Free Survival (PFS) - Central Review Assessment

The primary objective of this study is to compare progression-free survival (PFS), as assessed by blinded central review, of participants with advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gBRCA mutation breast cancer when treated with niraparib as compared to those treated with physician's choice single agent chemotherapy standards (eribulin, vinorelbine, gemcitabine or capecitabine). PFS is defined as the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier as per Response evaluation criteria in solid tumors (RECIST) version (v)1.1 as determined by central review assessment. Progressive Disease is defined as at least a 20 percent (%) increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including Baseline) and an absolute increase of \>= 5 millimeter (mm).

Time frame:
From the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier, up to 4 years
Reported as:
Median · Months
Progression Free Survival (PFS) - Central Review Assessment
MonthsPhysician's ChoiceNiraparib
Progression Free Survival (PFS) - Central Review Assessment3.1 (1.6 to 7.2)4.1 (2.9 to 4.5)
SecondaryOverall Survival

Overall Survival (OS) was defined as the time from randomization to the date of death of any causes.

Time frame:
From treatment randomization to date of death of any cause, up to 4 years
Reported as:
Median · Months
Overall Survival
MonthsPhysician's ChoiceNiraparib
Overall Survival15.8 (12.1 to 18.4)14.5 (11.7 to 17.2)
SecondaryNumber of Participants With Central BRCA Mutation Status

Blood samples were collected to evaluate central BRCA mutation status of participants. Baseline was defined as the most recent non-missing measurement prior to or on the first administration of study drug. Number of participants with central BRCA mutation status as BRCA1 positive only, BRCA2 positive only, Rearrangement only, BRCA1 and BRCA2 positive, BRCA1 positive and rearrangement, and BRCA2 positive and rearrangement were reported.

Time frame:
At Baseline (Cycle 1 Day1) (Cycle duration was 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Central BRCA Mutation Status
ParticipantsPhysician's ChoiceNiraparib
BRCA1 positive only3866
BRCA2 positive only2857
Rearrangement only37
BRCA1 and BRCA2 positive13
BRCA1 positive and rearrangement11
BRCA2 positive and rearrangement01
SecondaryNumber of Participants With Serious Adverse Events (SAE) and Non-serious Adverse Events (Non-SAE)

An adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect in a participant, whether or not considered related to the protocol treatment, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing participant hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an medically important event or reaction as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.

Time frame:
Up to 7 years
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAE) and Non-serious Adverse Events (Non-SAE)
ParticipantsPhysician's ChoiceNiraparib
SAE433
Non-SAE62134
SecondaryProgression Free Survival (PFS) - Investigator Assessment

PFS is defined as the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier as per RECIST version 1.1 as determined by Investigator assessment. Progressive Disease is defined as at least a 20 % increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including Baseline) and an absolute increase of \>= 5 mm.

Time frame:
Assessed up to 4 years
Reported as:
Median · Months
Progression Free Survival (PFS) - Investigator Assessment
MonthsPhysician's ChoiceNiraparib
Progression Free Survival (PFS) - Investigator Assessment3.1 (2.7 to 5.1)5.0 (4.2 to 5.5)
SecondaryTime to Treatment Failure

Time to treatment failure was defined from the date of randomization to progression or discontinuation of treatment for any reason, including but not restricted to disease progression, treatment toxicity and death.

Time frame:
Date of randomization to discontinuation of treatment for any reason, up to 4 years
Reported as:
Median · Months
Time to Treatment Failure
MonthsPhysician's ChoiceNiraparib
Time to Treatment Failure2.6 (1.6 to 3.2)4.3 (4.0 to 5.5)
SecondaryOverall Response Rate (ORR)

ORR was defined as the percentage of the participants who achieved a complete response (CR) or partial response (PR) to treatment evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR)=disappearance of all target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. Partial Response (PR)= at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the Baseline sum of diameters. Percentage values are rounded off up to 1 decimal.

Time frame:
Up to 4 years
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsPhysician's ChoiceNiraparib
Overall Response Rate (ORR)12.5 (5.6 to 23.2)21.4 (14.6 to 29.6)
SecondaryDuration of Response (DOR)

Duration of response was defined as the time from first documentation of response (confirmed CR or PR) until the time of first documentation of disease progression by RECIST v1.1 or death by any cause.

Time frame:
Up to 4 years
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPhysician's ChoiceNiraparib
Duration of Response (DOR)5.65 (5.65 to 14.78)4.14 (2.79 to 6.90)
Other pre-specifiedNumber of Participants With Minimally Clinically Important Difference (MCID) Status in European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-C30 (EORTC-QLQ-C30)

The number of participants with MCID status in EORTC-QLQ-C30 was planned to be evaluated.The EORTC- QLQ-C30 includes 30-items with single and multi-item scales. These include five functional scales (physical functioning, role functioning cognitive functioning, emotional functioning and social functioning), three symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss and financial difficulties). Response options are 1 to 4. The average score can be transformed to 0 to 100, a high score for functional scales/ GHS/QoL represents better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represents significant symptomatology.

Time frame:
Up to 7 years

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Euroqol 5 Dimension 5 Level (EQ-5D-5L) Dimension Scores by Visit

The number of participants with EQ-5D-5L scores by visit were planned to be evaluated. EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility,self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale(no problems, slight problems, moderate problems, severe problems and extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were to be converted to a single index score. Range for EQ-5D-5L index score is 0 (worst health) to 100 (best health), higher the score better the health status.

Time frame:
Up to 7 years

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Any Subsequent Therapies Post Discontinuation of Study Treatment and Association With Potential Survival Related Outcomes

The number of participants with any subsequent therapies post-discontinuation of study treatment and association with potential survival related outcomes were planned to be evaluated.

Time frame:
Up to 7 years

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Presence of Genetic and Non-genetic Biomarkers

Biomarkers include germline and tumor mutations including somatic BRCA1 and 2 mutations, reversion mutations, loss of heterozygosity as well as genome landscape and transcriptional or functional measures of homologous recombination (HR) deficiency were planned to be evaluated.

Time frame:
Up to 7 years

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Germline BRCA1 and BRCA2 Mutation Status in Association With Survival Related Outcomes

Participants with germline BRCA1 and BRCA2 mutation status in association with survival related outcomes were planned to be evaluated.

Time frame:
Up to 7 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Serious Adverse Events Related to New Malignancy

The number of participants with serious adverse events related to new malignancy were reported.

Time frame:
Up to 7 years
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events Related to New Malignancy
ParticipantsPhysician's ChoiceNiraparib
Number of Participants With Serious Adverse Events Related to New Malignancy02
SecondaryNumber of Participants With Subsequent Anticancer Therapies

The number of participants with subsequent anticancer therapies were evaluated. Data has been reported as per following categories: any new anitumoral therapy, any chemotherapy, any radiotherapy, any surgery, any hormonal therapy, any targeted agents, and any other treatment. Participants may have received more than one subsequent therapies.

Time frame:
Up to 7 years
Reported as:
Count of participants · Participants
Number of Participants With Subsequent Anticancer Therapies
ParticipantsPhysician's ChoiceNiraparib
Any new antitumoral therapy55108
Any chemotherapy4896
Any radiotherapy2248
Any surgery513
Any hormonal therapy1327
Any targeted agent therapy1922
Any other treatment817

Adverse events

Collected over All-cause mortality, Serious adverse events (SAEs) and non-serious AEs (non-SAEs) were collected up to 7 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Physician's Choice39/65 (60%)4/65 (6.2%)62/65 (95.4%)
Niraparib79/134 (59%)33/134 (24.6%)134/134 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventPhysician's ChoiceNiraparib
ThrombocytopeniaBlood and lymphatic system disorders0/6510/134
AnaemiaBlood and lymphatic system disorders0/659/134
NauseaGastrointestinal disorders0/655/134
PneumoniaInfections and infestations0/654/134
VomitingGastrointestinal disorders1/653/134
HeadacheNervous system disorders0/653/134
PainGeneral disorders1/651/134
PyrexiaGeneral disorders1/651/134
HypoaesthesiaNervous system disorders1/651/134
Language disorderNervous system disorders1/650/134
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPhysician's ChoiceNiraparib
AnaemiaBlood and lymphatic system disorders23/6591/134
NauseaGastrointestinal disorders24/6582/134
FatigueGeneral disorders29/6566/134
Weight decreasedInvestigations10/6553/134
VomitingGastrointestinal disorders11/6551/134
ConstipationGastrointestinal disorders11/6548/134
ThrombocytopeniaBlood and lymphatic system disorders4/6548/134
DiarrhoeaGastrointestinal disorders22/6519/134
HeadacheNervous system disorders10/6544/134
Platelet count decreasedInvestigations3/6543/134

Baseline characteristics

The centrally-confirmed intent-to-treat population is defined as all randomized participants with a central confirmation of germline BRCA mutation.

Age, Customized
Age, Customized(Participants)Physician's ChoiceNiraparibTotal
18-64 years67127194
65-74 years358
>=75 years134
Sex: Female, Male
Sex: Female, Male(Participants)Physician's ChoiceNiraparibTotal
Female68135203
Male303
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Physician's ChoiceNiraparibTotal
Hispanic or Latino6612
Not Hispanic or Latino50110160
Unknown or Not Reported151934
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Physician's ChoiceNiraparibTotal
Race — Ashkenazi Jewish descendant6511
Race — White or Caucasian59108167
Race — Black369
Race — Asian022
Race — Unknown178
Race — Missing279
08

Study locations

104 sites
  • GSK Investigational Site
    Tucson, Arizona 85710, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Fort Myers, Florida 33901, United States
  • GSK Investigational Site
    Miami, Florida 33176, United States
  • GSK Investigational Site
    Boston, Massachusetts 02111, United States
  • GSK Investigational Site
    Omaha, Nebraska 68114, United States
  • GSK Investigational Site
    Henderson, Nevada 89074, United States
  • GSK Investigational Site
    Clifton Park, New York 12065, United States
  • GSK Investigational Site
    Lake Success, New York 11042, United States
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Portland, Oregon 97225, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Nashville, Tennessee 37232, United States
  • GSK Investigational Site
    Dallas, Texas 75237, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    San Antonio, Texas 78217, United States
  • GSK Investigational Site
    Webster, Texas 77598, United States
  • GSK Investigational Site
    Weslaco, Texas 78596, United States
  • GSK Investigational Site
    Low Moor, Virginia 24457, United States
  • GSK Investigational Site
    Everett, Washington 98201, United States
  • GSK Investigational Site
    Seattle, Washington 98111, United States
  • GSK Investigational Site
    Green Bay, Wisconsin 54311, United States
  • GSK Investigational Site
    Aalst, 9300, Belgium
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Bruxelles, 1000, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Namur, 5000, Belgium
  • GSK Investigational Site
    Calgary, Alberta T2N 4N2, Canada
  • GSK Investigational Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • GSK Investigational Site
    Bordeaux, 33076, France
  • GSK Investigational Site
    Dijon Cedex, 21079, France
  • GSK Investigational Site
    Lille Cedex, 59020, France
  • GSK Investigational Site
    Lyon Cedex 08, 69373, France
  • GSK Investigational Site
    Montpellier, 34298, France
  • GSK Investigational Site
    Nantes cedex, 44202, France
  • GSK Investigational Site
    Paris Cedex 5, 75248, France
  • GSK Investigational Site
    Saint-Cloud, 92210, France
  • GSK Investigational Site
    Heraklion,Crete, 71110, Greece
  • GSK Investigational Site
    Maroussi, 15123, Greece
  • GSK Investigational Site
    Nea Kifissia, 14564, Greece
  • GSK Investigational Site
    Neo Faliro, 18547, Greece
  • GSK Investigational Site
    Thessaloniki, 57001, Greece
  • GSK Investigational Site
    Budapest, 1122, Hungary
  • GSK Investigational Site
    Debrecen, 4032, Hungary
  • GSK Investigational Site
    Miskolc, 3501, Hungary
  • GSK Investigational Site
    Nyiregyhaza, 4400, Hungary
  • GSK Investigational Site
    Pécs, 7624, Hungary
  • GSK Investigational Site
    Szeged, 6720, Hungary
  • GSK Investigational Site
    Reykjavik, IS-101, Iceland
  • GSK Investigational Site
    Haifa, 3109601, Israel
  • GSK Investigational Site
    Holon, 58100, Israel
  • GSK Investigational Site
    Kfar-Saba, 44281, Israel
  • GSK Investigational Site
    Rehovot, 76100, Israel
  • GSK Investigational Site
    Tel Aviv, 6423906, Israel
  • GSK Investigational Site
    Tel Hashomer, 52621, Israel
  • GSK Investigational Site
    Meldola (FC), Emilia-Romagna 47014, Italy
  • GSK Investigational Site
    Parma, Emilia-Romagna 43100, Italy
  • GSK Investigational Site
    Rimini, Emilia-Romagna 47900, Italy
  • GSK Investigational Site
    Viterbo, Lazio 01100, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Cremona, Lombardia 26100, Italy
  • GSK Investigational Site
    Milano, Lombardia 20141, Italy
  • GSK Investigational Site
    Ancona, Marche 60020, Italy
  • GSK Investigational Site
    Lecce, Puglia 73100, Italy
  • GSK Investigational Site
    Prato, Toscana 59100, Italy
  • GSK Investigational Site
    Legnago (VR), Veneto 37045, Italy
  • GSK Investigational Site
    Leiden, RC, 2333 ZA, Netherlands
  • GSK Investigational Site
    Limburg, 6229HX, Netherlands
  • GSK Investigational Site
    Zwolle, 8025 AB, Netherlands
  • GSK Investigational Site
    Lodz, 93-513, Poland
  • GSK Investigational Site
    Raciborz, 47-400, Poland
  • GSK Investigational Site
    Coimbra, 3000-075, Portugal
  • GSK Investigational Site
    Lisbon, 1400-038, Portugal
  • GSK Investigational Site
    Porto, 4200-072, Portugal
  • GSK Investigational Site
    Barcelona, 8035, Spain
  • GSK Investigational Site
    Burgos, 09005, Spain
  • GSK Investigational Site
    Cáceres, 10003, Spain
  • GSK Investigational Site
    L'Hospitalet de Llobregat, 8907, Spain
  • GSK Investigational Site
    Lerida, 25198, Spain
  • GSK Investigational Site
    Lugo, 27003, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Pamplona, 31008, Spain
  • GSK Investigational Site
    Valencia, 46009, Spain
  • GSK Investigational Site
    Valencia, 46015, Spain
  • GSK Investigational Site
    Vigo, 36312, Spain
  • GSK Investigational Site
    Southampton, Hampshire SO16 6YD, United Kingdom
  • GSK Investigational Site
    Northwood, Middlesex HA6 2RN, United Kingdom
  • GSK Investigational Site
    Headington, Oxford, Oxfordshire OX3 7LJ, United Kingdom
  • GSK Investigational Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • GSK Investigational Site
    Bebington, Wirral, CH63 4JY, United Kingdom
  • GSK Investigational Site
    Belfast, BT9 7AB, United Kingdom
  • GSK Investigational Site
    Edinburgh, EH4 2XU, United Kingdom
  • GSK Investigational Site
    Glasgow, G11 6NT, United Kingdom
  • GSK Investigational Site
    London, NW1 2PG, United Kingdom

Showing the first 100 of 104 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2014 to primary completion in May 2018, 50 months.

Results were first posted in Aug 2020, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2013
First posted
Jul 23, 2013
StartActual
Feb 25, 2014
Primary completionActual
May 23, 2018
CompletionActual
Oct 26, 2021
Results first posted
Aug 27, 2020
Last update
Nov 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01905592
Lead sponsor
Tesaro, Inc.
Collaborators
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Myriad Genetic Laboratories, Inc., US Oncology Research, Sarah Cannon, Facing Our Risk of Cancer Empowered
Responsible party
Sponsor
First posted
Jul 23, 2013
Start date
Feb 25, 2014
Primary completion
May 23, 2018
Completion
Oct 26, 2021
Results posted
Aug 27, 2020
Last update
Nov 15, 2022

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion